Investing
Regeneron preliminary Q4 US sales of Eylea below expectations
© Reuters. FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company’s Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Brendan McDermid/File Photo
(Reuters) – Regeneron (NASDAQ:) Pharmaceuticals on Monday reported eye drug Eylea’s fourth-quarter U.S. preliminary sales, which came below Wall Street expectations, as the company’s blockbuster product faced pressure from a rival.
The company garnered $1.34 billion in U.S. sales, while Wells Fargo analyst Mohit Bansal last week pegged consensus Wall Street estimates for U.S. sales of Eylea at $1.53 billion.
Eylea, jointly developed with Bayer AG (ETR:), has driven Regeneron’s earnings for years, but its sales have come under pressure, partly from Roche’s Vabysmo that secured U.S. approval in 2022.
Regeneron has set its hopes on a higher-dose version of Eylea. U.S. sales of the version came in at about $123 million in the quarter, the company said. (This story has been corrected to say Roche’s Vabysmo was approved in 2022, not last year, in paragraph 3)
Read the full article here
-
Side Hustles7 days ago
3 Steps You Can’t Miss When Growing Your Business
-
Investing7 days ago
How I Transformed My Business by Letting Go of Low-Value Tasks
-
Make Money7 days ago
Here’s the Typical American’s Income at Every Age. How Do You Compare?
-
Investing7 days ago
Germany stocks lower at close of trade; DAX down 0.65% By Investing.com
-
Side Hustles5 days ago
How Your Body Language Can Help Win a Disagreement
-
Passive Income5 days ago
Are You Running Your Business, or Is Your Business Running You?
-
Investing5 days ago
7 Marketing Strategies to Help Your Startup Grow and Scale
-
Side Hustles6 days ago
How to Develop Empowered Leaders Within Your Own Team